JNJ - Johnson & Johnson
| Previous Close | 137.17 |
| Open | 137.61 |
| Bid | 138.16 x 800 |
| Ask | 138.16 x 1000 |
| Day's Range | 137.47 - 138.82 |
| 52 Week Range | 118.62 - 148.99 |
| Volume | 3,089,115 |
| Avg. Volume | 7,960,095 |
| Market Cap | 367.675B |
| Beta (3Y Monthly) | 0.66 |
| PE Ratio (TTM) | 24.63 |
| EPS (TTM) | 5.61 |
| Earnings Date | Apr 16, 2019 |
| Forward Dividend & Yield | 3.60 (2.62%) |
| Ex-Dividend Date | 2019-02-25 |
| 1y Target Est | 144.71 |
Market Realist•15 minutes agoAnalysts Are Divided on Johnson & Johnson Stock
How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have given Johnson & Johnson (JNJ) a 12-month consensus target price of $144.71, 5.50% higher
- Zacks•22 hours ago
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $137.35, moving -0.19% from the previous trading session.
- Investing.com•yesterday
UnitedHealth Shares Finding Their Mojo Again
Investing.com - UnitedHealth Group (NYSE:UNH) has been a big reason why the Dow has held its own lately.
- Zacks•yesterday
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
- Motley Fool•4 days ago
5 Recession-Proof Stocks
Almost no one is thinking about the fifth company, and therein lies opportunity.
- Zacks•4 days ago
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
- Zacks•4 days ago
J&J Seeks Approval for Darzalex in Expanded Patient Group
J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.
Motley Fool•5 days agoJabil Circuit Inc (JBL) Q2 2019 Earnings Conference Call Transcript
JBL earnings call for the period ending February 28, 2019.
- CNBC•5 days ago
Cramer: Five 'perils' of investing in individual stocks
Jim Cramer takes a look at some of the biggest headlines of the week that have rocked stocks on the market.
- CNBC•5 days ago
Cramer: Five 'perils' of investing in individual stocks
"I'm going to give you five reasons why it's so hard to make money in the stock market ... [preparing] you for the inevitable pain that comes with owning individual stocks," CNBC's Jim Cramer says. "If you want stock market exposure, the best way to get it is with index funds, index funds, and more index funds," he says. Investors must be aware of potential rewards and beware the potential risks when buying a stock because anything can happen on the stock market, CNBC's Jim Cramer said Thursday.
- Barrons.com•5 days ago
3 More Outstanding Funds for Dividend Investors
The Barron’s Income column has presented the five top-performing dividend ETFs and the five leading actively managed dividend mutual funds over the past five years. Here are three more strongly performing actively managed dividend funds.
- Reuters•5 days ago
US STOCKS-Wall St near flat as trade deal outlook uncertain
U.S. stocks were little changed in late afternoon trading on Thursday amid uncertainty over when a trade deal between the United States and China would be reached. President Donald Trump said the United States was doing very well in trade talks with China, but could not say whether a final deal would be reached. Trump and Chinese President Xi Jinping had been expected to hold a summit at the president's Mar-a-Lago property in Florida later this month, but no date has been set for a meeting.
- Motley Fool•5 days ago
3 Penny Stocks That Could Make You Rich -- or Regretful
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
- Reuters•5 days ago
US STOCKS-Wall Street muted on trade uncertainty, housing data disappoints
U.S. stocks flitted between gains and losses on Thursday as uncertainty over when a trade deal between the United States and China would be reached clouded sentiment. Wall Street's main indexes briefly moved higher after President Donald Trump said the United States was doing very well in trade talks with China, but could not say whether a final deal would be reached.
- CNBC•5 days ago
Johnson & Johnson shares slip after California jury orders it to pay $29 million in latest talcum cancer trial
A California jury on Wednesday ordered Johnson & Johnson to pay $29 million to a woman who alleged that asbestos in the company's talcum-powder-based products, including Johnson's Baby Powder, caused her mesothelioma.
- Barrons.com•5 days ago
J&J Takes Another Hit in Fight Against Asbestos Claims
Johnson & Johnson’s baby-powder problems continued Wednesday after a California jury decided the company must pay $29 million to a woman who claimed the company’s talcum powder-based products gave her cancer.
- Reuters•5 days ago
US STOCKS-Wall St dips on trade uncertainty, weak new home sales data
U.S. stocks dipped on Thursday weighed down by concerns of a delay in trade talks between the United States and China, and data which showed a higher-than-expected fall in new home sales in January. A meeting between President Donald Trump and China's Xi Jinping to sign an agreement to end their trade dispute was more likely to take place in April at the earliest, Bloomberg reported, a day after Trump said he was in no rush to complete a trade pact with China.
Yahoo Finance•5 days agoDollar General falters, GE’s forecast disappoints, Apple may expand streaming service
Dollar General, GE, Apple, Snap and Johnson & Johnson are the companies to watch.
- Reuters•5 days ago
US STOCKS-Wall Street set for muted open as trade uncertainty overhangs
Wall Street was set to open flat on Thursday as uncertainty of trade talks between the United States and China offset optimism after Britain's parliament voted to reject a disorderly Brexit. Bloomberg reported that a meeting between President Donald Trump and China's Xi Jinping to sign an agreement to end their trade dispute won't occur this month and is more likely to happen in April at the earliest. A day earlier, U.S. President Donald Trump said he was in no rush to complete a trade pact with China.
- CNBC•5 days ago
Stocks making the biggest moves premarket: Boeing, Tesla, General Electric, Facebook & more
GE issued a 2019 outlook, saying it would earn an adjusted 50 cents to 60 cents per share for 2019, compared to the 70 cents a share consensus estimate. GE CEO Larry Culp said the company's challenges are "complex but clear" and that he expects 2020 and 2021 to be significantly better. Boeing BA — Boeing remains on watch after the Federal Aviation Administration grounded its fleet of 737 MAX jets while it investigates the causes of two recent overseas crashes involving the jet.
- Investing.com•5 days ago
Stocks - Boeing, Facebook Fall in Premarket; Apple Rises
· General Electric (NYSE:GE) stock recovered to be up 1.6% by 8:15 AM ET (12:15 GMT), after falling earlier as the company told shareholders it expects this year's earnings to be below analysts' forecasts due partly to the troubles of its power business struggles. GE said it expects 2019 adjusted earnings to be between $0.50 and $0.60 a share, less than the $0.70 consensus forecast.
Reuters•6 days agoCalifornia jury awards $29 million to woman with cancer who used J&J talc
A California jury on Wednesday awarded $29 million to a woman who said that asbestos in Johnson & Johnson's talcum-powder-based products caused her cancer. The verdict, in California Superior Court in ...
- Reuters•6 days ago
UPDATE 2-California jury awards $29 mln to woman with cancer who used J&J talc
A California jury on Wednesday awarded $29 million to a woman who said that asbestos in Johnson & Johnson's talcum-powder-based products caused her cancer. The verdict, in California Superior Court in Oakland, marks the latest defeat for the healthcare conglomerate facing more than 13,000 talc-related lawsuits nationwide. J&J said it would appeal, citing "serious procedural and evidentiary errors" in the course of the trial, saying lawyers for the woman had fundamentally failed to show its baby powder contains asbestos.
